These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26742011)

  • 21. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial.
    Hewitson P; Ward AM; Heneghan C; Halloran SP; Mant D
    Br J Cancer; 2011 Aug; 105(4):475-80. PubMed ID: 21829202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm.
    Kearns B; Whyte S; Seaman HE; Snowball J; Halloran SP; Butler P; Patnick J; Nickerson C; Chilcott J
    Br J Cancer; 2016 Feb; 114(3):327-33. PubMed ID: 26766733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of repeat participation in the NHS bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Br J Cancer; 2015 Jan; 112(1):199-206. PubMed ID: 25429524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women.
    Blanks RG; Benson VS; Alison R; Brown A; Reeves GK; Beral V; Patnick J; Green J
    Br J Cancer; 2015 Apr; 112(9):1562-7. PubMed ID: 25742470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High test positivity and low positive predictive value for colorectal cancer of continued faecal occult blood test screening after negative colonoscopy.
    Brown JP; Wooldrage K; Wright S; Nickerson C; Cross AJ; Atkin WS
    J Med Screen; 2018 Jun; 25(2):70-75. PubMed ID: 28467146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial.
    Hirst Y; Skrobanski H; Kerrison RS; Kobayashi LC; Counsell N; Djedovic N; Ruwende J; Stewart M; von Wagner C
    Br J Cancer; 2017 May; 116(11):1408-1414. PubMed ID: 28441381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive ability and personality as predictors of participation in a national colorectal cancer screening programme: the English Longitudinal Study of Ageing.
    Gale CR; Deary IJ; Wardle J; Zaninotto P; Batty GD
    J Epidemiol Community Health; 2015 Jun; 69(6):530-5. PubMed ID: 25648994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England.
    von Wagner C; Baio G; Raine R; Snowball J; Morris S; Atkin W; Obichere A; Handley G; Logan RF; Rainbow S; Smith S; Halloran S; Wardle J
    Int J Epidemiol; 2011 Jun; 40(3):712-8. PubMed ID: 21330344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Race and Socioeconomic Status With Colorectal Cancer Screening, Colorectal Cancer Risk, and Mortality in Southern US Adults.
    Warren Andersen S; Blot WJ; Lipworth L; Steinwandel M; Murff HJ; Zheng W
    JAMA Netw Open; 2019 Dec; 2(12):e1917995. PubMed ID: 31860105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-Reported And Objectively Recorded Colorectal Cancer Screening Participation In England.
    Lo SH; Waller J; Vrinten C; Wardle J; von Wagner C
    J Med Screen; 2016 Mar; 23(1):17-23. PubMed ID: 26408533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.
    Geraghty J; Butler P; Seaman H; Snowball J; Sarkar S; Blanks R; Halloran S; Bodger K; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2156-62. PubMed ID: 25225905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population.
    Kaushal A; Hirst Y; Tookey S; Kerrison RS; Marshall S; Prentice A; Vulkan D; Duffy S; von Wagner C
    Prev Med; 2020 Dec; 141():106268. PubMed ID: 33022321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy.
    Bonello B; Ghanouni A; Bowyer HL; MacRae E; Atkin W; Halloran SP; Wardle J; von Wagner C
    BMC Gastroenterol; 2016 Sep; 16(1):113. PubMed ID: 27618798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lack of information engagement among colorectal cancer screening non-attenders: cross-sectional survey.
    Kobayashi LC; Waller J; von Wagner C; Wardle J
    BMC Public Health; 2016 Jul; 16():659. PubMed ID: 27473593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
    Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
    Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Screening for colorectal cancer in Italy, 2010 survey].
    Zorzi M; Fedato C; Grazzini G; Sassoli de' Bianchi P; Naldoni C; Pendenza M; Sassatelli R; Senore C; Visioli CB; Zappa M
    Epidemiol Prev; 2012; 36(6 Suppl 1):55-77. PubMed ID: 23293271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-neoplastic findings at colonoscopy after positive faecal occult blood testing: data from the English Bowel Cancer Screening Programme.
    Bevan R; Lee TJ; Nickerson C; Rubin G; Rees CJ;
    J Med Screen; 2014 Jun; 21(2):89-94. PubMed ID: 24644029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexible sigmoidoscopy following a positive faecal occult blood test within a bowel screening programme may reduce the detection of neoplasia.
    Mansouri D; McMillan DC; Roxburgh CS; Moug SJ; Crighton EM; Horgan PG
    Colorectal Dis; 2013 Nov; 15(11):1375-81. PubMed ID: 23927751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.